Drug Profile


Alternative Names: BG 8301; Bioleukin; Bioleukin IL-2; Imunace; S 6820

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Immunostimulants; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer
  • No development reported HIV infections
  • Discontinued Cancer metastases

Most Recent Events

  • 23 Feb 2005 Discontinued - Phase-II for Cancer metastases in Japan (Injection)
  • 23 Feb 2005 Discontinued - Preclinical for Cancer in South Korea (unspecified route)
  • 18 Nov 2003 No development reported - Clinical-Phase-Unknown for HIV infections treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top